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ABSTRACT 
Human papillomavirus (HPV)-negative (-ve) oropharyngeal squamous cell carcinomas 
(OPSCCs) are associated with poorer overall survival (OS) compared to HPV-positive (+ve) 
OPSCCs. The major obstacle to improving outcomes of HPV -ve patients is the absence of 
good biomarkers. Herein, we investigated the role of centrosome amplification (CA) as a 
prognostic marker in HPV –ve OPSCCs. We first quantitatively assessed CA in OPSCC tumor 
samples and found that HPV -ve OPSCCs exhibit higher CA compared to HPV +ve OPSCCs, 
and was associated with poor OS even after adjusting for potentially confounding variables. 
Further, the expression of genes associated with hypoxia and CA was significantly higher in 
HPV -ve OPSCCs than in HPV +ve OPSCCs. We further uncovered a mechanism by which 
hypoxia-induced HIF-1α downregulates miR-34a resulting in cyclin D1 overexpression and 
rampant CA in HPV -ve OPSCCs. Our findings demonstrate that assessment of CA may aid in 
therapeutic decision-making for these patients.  
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1 INTRODUCTION  
1.1 Purpose of Study  
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide1. Although the incidence and mortality rate of HNSCC are declining globally, there is 
a gradual increase in incidence rate of oropharyngeal squamous cell carcinomas (OPSCCs) in 
recent years2,3. OPSSC is a type of HNSCC, which includes cancer of tonsils, base of tongue, 
back of the roof of the mouth and the side and back walls of the throat. A major contributing 
factor to the increase in incidence rate of OPSSCs is human papillomavirus (HPV) infection4-9. 
Studies have shown that HPV positive (+ve) OPSCC patients respond better to treatment when 
compared with HPV negative (-ve) OPSCCs. A retrospective study by Ang et al. showed that in 
a randomized trial comparing accelerated-fractionation with standard-fractionation radiotherapy, 
each combined with cisplatin therapy, HPV +ve OPSCC patients had better rates of three year 
overall survival (82.4%) compared to that of their HPV -ve counterparts (57.1%) (overall survival 
was taken from time of randomization till the death)11. The relatively more favorable prognosis 
within the HPV +ve group has led clinicians to focus on treatment de-escalation in these 
patients in an effort to achieve similar treatment efficacy with reduced toxicity 12,13. Little success 
has, however, been achieved with improving survival rates for HPV -ve patients despite the use 
of novel treatment strategies. For example, the Eastern Cooperative Oncology group observed 
a 2-year overall survival of 95% for HPV +ve patients as compared to 62% in HPV -ve patients 
treated with induction chemotherapy followed by concurrent chemoradiotherapy14. This drastic 
survival difference between the two groups was again observed in a separate study of patients 
treated with concurrent radiotherapy and cisplatin using either conventional fractionation or 
accelerated fractionation15. In the absence of a good therapeutic target, conventional 
chemotherapy is unfortunately still the mainstay of treatment for HPV -ve OPSCC patients 
whose prognosis remains grim.  
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Treatment decisions for OPSCC patients were made based on disease stage and tumor 
location, without taking into account the tumor’s HPV status.10 Recent studies have suggested 
that HPV +ve and HPV -ve OPSCCs are biologically unique entities,11,16 with differing tumor 
biology and characteristics. In recognition of the unique character and prognosis of the latter, a 
new stage classification has been introduced for HPV +ve OPSCC in the 8th edition TNM and 
p16 staining serves as a surrogate for HPV status and choice of staging system. Studies have 
also reported that HNSCC is a heterogeneous disease with higher chromosomal instability 
(CIN) reported in HPV -ve (50% more mutational load) compared to the HPV +ve HNSCCs17,18. 
Inactivation of tumor suppressor genes such TP53 and CDKNA2 and the oncogenic activation 
of the CCND1 have been shown to be crucial for pathogenesis and disease progression in HPV 
-ve HNSCCs19. By contrast, inactivation of the tumor suppressor genes and activation of 
oncoproteins in HPV +ve tumors has been linked to the viral E6 and E7 oncoproteins20. A key 
feature of E6 and E7 oncoproteins is that they both work to induce centrosome amplification 
(CA),21-23 which is hailed as a hallmark of cancer and a critical driver of chromosomal instability 
that fuels tumorigenesis, tumor progression, drug resistance and, as a result, poor prognosis24. 
CA can be numerical (increase in the number of centrosomes) as well as structural (increase in 
size of centrosomes) and can arise in multiple ways, including failure of the cell to undergo 
cytokinesis, inappropriate replication of centrosomes, and de novo generation25. In cancer cells, 
excess centrosomes cluster into two polar groups during mitosis, giving rise to pseudo-bipolar 
spindles. Merotelic attachment of individual kinetochores to more than one spindle pole is a 
frequent occurrence26. Such inappropriate attachments can cause missegregation of whole 
chromosomes and/or chromosomal breakage.  Furthermore, clustered supernumerary 
centrosomes are inherited by progeny cells, leading to a perpetuation of CIN in the cell 
lineage27.  
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Past genomic analyses of HNSCCs have described CIN to be a more prominent feature 
in HPV -ve tumors than in HPV +ve tumors28,29. However, due to the absence of the E6 and E7 
oncoproteins that normally drive CA in HPV +ve HNSCCs, the origin and potential involvement 
of CA in driving the CIN observed in HPV -ve HNSCCs has been overlooked. Instead, attention 
has focused on upregulation of DNA damage response (DDR) proteins such as Aurora A kinase 
and PLK1 as major factors contributing to CIN in HPV -ve HNSCCs30. Both Aurora A and PLK1 
promote CIN by deregulating the spindle assembly checkpoint, resulting in chromosome 
missegregation and amplification of centrosomes31,32. Aurora A kinase inhibitors, when used in 
combination with Wee1 inhibitors or cetuximab, (directed against EGFR) have shown promise in 
treating HPV -ve OPSCC33,34. Furthermore, the tumor suppressor, p53, that has been implicated 
in the regulation of centrosome duplication and CA is often mutated in HNSCCs35-37. Therefore, 
we reasoned that CA may be a readily quantifiable prognostic marker and druggable target for 
HPV -ve tumors. 
Another major contributing factor underlying poorer prognosis and survival outcomes in 
HPV -ve cancers is tumor hypoxia. Tumor hypoxia has long been known to be associated with 
poor responses to radiotherapy and chemotherapy38. A recent study has shown that HPV -ve 
oropharyngeal tumors display higher tumor hypoxia39.  Additionally, reduced partial pressure of 
oxygen inside tumors plays a significant role in overexpression of Aurora-A/STK1540, and this 
overexpression results in CA41, chromosomal instability, and aneuploidy. Also, there are 
literature evidences that support hypoxia-mediated overexpression of PLK4, which has been 
well documented to induce CA.42 Recently, we have shown that hypoxic tumor 
microenvironment can induce CA via the stabilization of the transcriptional factor HIF-1α in 
breast cancer, facilitating an aggressive disease course.43 Thus, there is mounting evidence that 
hypoxia-associated CA may underlie the aggressive disease course and treatment resistance of 
HPV -ve OPSCCs. 
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No studies to date have reported quantitation of centrosomal aberrations in OPSCCs 
with inherently different HPV status. Herein, we performed a thorough quantitative analysis of 
centrosomal aberrations in OPSCC tumors to establish differences in incidence and severity of 
CA between HPV +ve and HPV -ve OPSCC patients. Interestingly, we found that HPV -ve 
OPSSCs exhibited significantly higher CA when compared with the HPV +ve OPSCCs, and CA 
was associated with the poor overall survival in HPV -ve OPSCCs. Furthermore, we also 
established a strong association between CA and HIF-1α expression in HPV -ve OPSCCs. Our 
results indicated HPV -ve tumors show higher expression of HIF-1α and was correlated with the 
higher CA percentage. In addition, we found that HPV -ve tumors exhibited higher expression of 
CA-associated protein cyclin D1. To confirm the molecular association of HIF-1α and CA in 
OPSCC, we performed a series of in silico analyses. Firstly, we used publicly available GEO 
database to show strong correlation between the 26-gene hypoxia signature and a novel 7-gene 
CA signature. With emerging new data for the role of miRNAs in OPSCCs, we uncovered the 
possible function of HIF-1α regulated miRNA-34a in driving CA by inducing expression of cyclin 
D1 in HNSCCs. Taken together, these results shed new light on the drivers of tumor biology in 
HPV -ve tumors and emphasize the role of CA as new prognostic marker and actionable target 
to improve outcomes in HPV -ve OPSCCs. 
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2 MATERIALS AND METHODS 
 
2.1 Clinical tissue samples  
Formalin-fixed paraffin embedded OPSCC TMA sections of tonsil, base of tongue, and 
soft palate tumors (ICART4 cohort) were procured from the Poznan Cancer Center in 
Poland (ICART member). Patients were diagnosed between YEAR 2007 and 2014, and 
based on the location of tumor (tonsil, base of tongue and soft palate) the patients were 
selected for the TMA construction. Clinicopathologic characteristics of the patients are 
provided in Table 1. The Institutional Review Board of Greater Poland Cancer Centre, 
Poznan, PL approved all aspects of the study. Methods were carried out in “accordance” 
with approved guidelines stipulated in MTAs and DUAs between Greater Poland Cancer 
Centre, Poznan, PL and Georgia State University. Informed consent was obtained from all 
subjects.  
2.2 HPV analysis  
The detection of high risk HPV was performed using GP5+/GP6+ HPV DNA PCR with 
enzyme-immunoassay (EIA). For genotyping of the viral DNA, the Luminex platform was 
used for bead-based array.  The EIA detected 14 HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68. globin PCR was used to test for sample quality post-DNA 
extraction77.  
2.3 Immunohistochemistry of Cyclin D1 and HIF-1α and scoring. 
The initial steps from deparaffinization to antigen retrieval are the same as those for 
immunofluorescence. The tissues were then blocked with Ultravision Protein Block 
(ThermoFisher, Waltham, MA) for 30 minutes followed by hydrogen peroxide block with 
Ultravision Hydrogen Peroxide Block (ThermoFisher) for 10 minutes. The tissues were then 
immunolabeled with HIF-1α antibody (Abcam, Cambridge, MA) or cyclin D1 (ThermoFisher) 
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for 1 hour. After 3X washes in TBST, the slides were subjected to secondary antibody 
incubation using Anti-Rabbit HRP (Biocare, Pacheco, CA) for 1 hour. Enzymatic detection 
was performed using DAB Chromogen Kit (Biocare). Nuclear HIF-1α and cyclin D1 staining 
was categorized as 0=none, 1=low, 2=moderate, and 3=high. The percentage of positive 
cells, defined to be 1+ staining intensity, from around 500 cells was determined. The 
weighted index (WI) for each sample was calculated as the product of percent cell positivity 
and staining intensity.  
2.4 Immunofluorescence staining   
TMA slides were deparaffinized in the oven at 60°C for 30 minutes followed by 3 washes 
of in xylene and rehydration in series of washes in 100%, 95%, 70%, and 50% ethanol. 
Antigen retrieval was done by heating in a pressure cooker with citrate buffer (pH 6.0). The 
tissues were blocked with 5% BSA in PBS solution with 0.1% Triton X for 30 minutes. After 
blocking, primary antibody incubation with γ-tubulin (Sigma, St. Louis, MO) at a dilution of 
1:1000 was performed for 1 hour at room temperature. The tissues were then washed 3X 
with PBS after which incubation with secondary antibody (Alexa-488 anti-mouse) was done 
at room temperature for 1 hour at a dilution of 1:2000. After 3X washes in PBS, coverslips 
were mounted with Prolong-Gold Antifade with DAPI (Invitrogen, Waltham, MA).  
2.5 Quantification of both structural and numerical centrosome amplification 
We define CA as both structural and numerical aberration of centrosomes. The TMA’s 
were immunostained for γ-tubulin were observed with Zeiss LSM 700 confocal microscope 
(Ziess, Oberkochen, Germany) for centrosome amplification. At least 10 fields were imaged 
at 63X to capture enough nuclei and centrosomes. Analyses of images were performed 
using Imaris software that provided the capability to visualize the images in 3D. Interphase 
nuclei with more than two associated centrosomes were considered to exhibit numerical 
CA. Also, interphase nuclei associated with centrosomes whose 3-dimensional volume 
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exceeded the defined cut-off value of 0.7um3 were deemed to exhibit structural CA. A total 
of at least 250 nuclei were counted for each tissue. Percentage of CA was obtained by 
adding percentage of cells containing either structurally amplified centrosomes or 
numerically amplified centrosomes, or both.  
2.6 Drug Sensitivity Test 
We obtained the drug sensitivity data of CDK4/6 inhbitor palbociclib and Aurora A inhibitor 
ZM447439, in HNSSC cancer cell lines from www.cancerrxgene.org which contains drug 
sensitivity information of anticancer drugs in multiple cancer cell lines. Cell lines were 
divided into HPV +ve and HPV -ve based on the HPV status as per literature and IC-50 
values were plotted against cell lines for each drug. Students’ t-test was used to see if the 
two groups differ in sensitivity to Palbociclib and ZM447439.  
2.7 Statistical analyses 
For clinical data as well as the in silico data analysis patient’s overall survival was used as 
the endpoint for survival analysis. Log-rank test was applied to test the differences among 
Kaplan Meier survival curves. The cutoff points that we found for CA and HIF1-a were those 
which maximized survival differences between high- and low-risk subgroups. The test of 
group mean differences shown in Box-Whisker Plots are based on Mann–Whitney U test. In 
cases with  more than two groups, the difference was evaluated by the Kruskal–Wallis test. 
Statistical analysis was performed using SAS software 9.4(SAS Institute Inc., Cary, NC). 
For the survival model used in in silco analysis with individual genes, each gene was split 
into a high and low expression group by optimizing the log-rank test statistic and the hazard 
ratio parameter estimate for the high expression group was determined. High expression 
gene groups with negative impact on survival had a positive parameter estimate while 
genes that correlated positively with good prognosis had a negative parameter estimate. 
The total weighted sum, for each patient, was generated by adding the parameter estimates 
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for each gene, which had above threshold expression (if they were in the low expression 
group they were given a 0 for that gene weight). The cutoff between high and low weighted 
scores was similarly derived by finding the optimal log rank statistic.  
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3 RESULTS 
3.1 HPV -ve OPSCCs exhibit significantly higher CA than HPV +ve OPSCCs and CA is 
associated with poor overall survival in HPV -ve OPSCCs   
Previous studies in our lab have shown that CA can serve as a poor prognosis 
biomarker in multiple malignancies including breast cancer, pancreatic cancer, and serous 
ovarian adenocarcinoma44-46. Given the higher expression of DDR genes in HPV -ve 
OPSCC, we postulated that HPV -ve tumors will exhibit significant CA. Since no rigorous 
and quantitative studies to date have compared CA in HPV +ve and -ve OPSCCs, we 
visualized centrosomes in resection samples from 98 OPSCC patients (n=47 HPV +ve and 
n=51 HPV -ve samples) (ICART4 cohort). In order to measure the degree of structural and 
numerical CA, we performed fluorescent immunostaining of our tissue samples.  The 
centrosomes (red) were stained with γ-tubulin and the nuclei (blue) with DAPI. We then 
imaged the tissues to capture images 10 visual fields at 20x using Zeiss LSM 700 confocal 
microscope (Oberkochen, Germany). Within each field, we selected regions containing 
distinguishable nuclei and quantified the number and volume of g-tubulin foci for each 
nucleus to assess numerical and structural CA, respectively.  250 nuclei in total were 
counted at random using Imaris software that allowed us to visualize the nuclei and 
centrosomes in 3D. We defined “numerical” amplification as interphase nuclei associated 
with more than two centrosomes, and “structural” amplification was defined as nuclei 
associated with at least one centrosome that had a volume greater than 0.7 µm3. This 
threshold value was determined after past studies in our lab that defined the normal 
volumetric range of centrosomes across different cancer types, including breast, pancreas, 
bladder and OPSCCs, in which 500 centrosomes for each cancer type were counted from 
tissues of adjacent uninvolved cancer patients and normal tissues. Then an average normal 
range of volumes was determined, above which was considered to be abnormal. Then, we 
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independently counted cells (nuclei) that harbored numerical amplification of centrosomes 
and cells that harbored structural amplification from our total of 250. A percentage was 
calculated for each type of amplification and the values were added to determine a CA 
value for each sample. HPV status for the samples was determined by the DNA PCR 
utilizing the enzyme immunoassay (details added in the Materials and Methods). Patient 
cohort details are shown in Table 1. Surprisingly, Wilcoxon distribution scores revealed that 
the HPV -ve samples exhibited significantly higher CA (numerical and structural) when 
compared with the HPV +ve samples (p=0.034; Fig. 2A). In line with previous studies, we 
observed that HPV -ve OPSCCs were associated with poorer overall survival when 
compared with HPV +ve OPSCCs. (p=0.0062; HR=4.629) (Fig. 1B). Interestingly, when we 
stratified all the patients into low- and high-CA groups (threshold used was the one that 
minimized log-rank p-value) within HPV +ve and HPV -ve subgroups (Fig. 1C), we 
observed that high-CA HPV -ve OPSCCs were associated with poorer overall survival than 
the high-CA HPV +ve OPSCCs (p=0.02; HR=7.7). Furthermore, within HPV -ve OPSCCs, 
the high CA group was associated with poorer overall survival when compared with the low 
CA HPV -ve OPSCCs. This association stayed significant (p=0.03; HR=5.4) in our 
multivariable analysis when potentially confounding factors like smoking, alcohol 
consumption, grade, and tumor stage were included (Table 2). No significant differences 
were found between overall survival of low-CA HPV +ve and HPV -ve subgroups. These 
findings contrast with the long-held belief that CA is higher in HPV +ve tumors that harbor 
the E6 and E7 viral oncoproteins. To further test the clinical significance of CA, we 
evaluated associations between CA and other clinical parameters. In line with the 
understanding that CA drives tumor progression, our data (Fig. 2B) showed that among 
HPV -ve tumors, higher CA was associated with higher disease stage (p=0.1013). 
Moreover, HPV -ve tumors displayed higher CA compared to that of stage-matched (stage 
III and stage IV; p=0.1225 and p=0.0551, respectively) HPV +ve tumors (Fig. 2C, 2D). In 
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sum, these findings suggest that HPV -ve OPSCCs exhibit higher CA when compared with 
HPV +ve OPSCCs and higher CA in the HPV -ve OPSCCs is associated with poorer overall 
survival. 
 
 
        Figure 1. HPV -ve tumors show higher CA and poorer prognosis than HPV +ve tumors 
 (A) Confocal micrographs showing numerical and structural CA in HPV +ve and HPV -ve 
tumor sections OPSCC tissue sections were immunostained for centrosomes (γ-tubulin, 
red) and counterstained with DAPI (blue). Scale bar (white), 20µm. (B) and (C) Kaplan 
Meier survival curves representing the survival probabilities of HPV -ve (n=51) and HPV 
+ve (n=47) OPSCC patients (HR=4.629, p=0.0062) and the survival probabilities of high-CA 
HPV -ve (n=30) and HPV +ve (n=24) OPSCC patients (HR=7.7; p=0.02), respectively. 
 
12 
 
Figure 2. Analysis of CA in OPSCC clinical samples 
(A) Distribution of % cells with CA (structural and numerical) in HPV -ve (n=51) and HPV +ve 
(n=47) patients (p=0.0340). (B) Distribution of CA between stage III (n=15) and stage IV (n=28) 
in HPV -ve patients (p=0.1013). (C) Distribution of CA between HPV -ve (n=15) and HPV +ve 
(n=9) stage III patients (p=0.1225). (D) Distribution of CA between HPV -ve (n=28) and HPV 
+ve (n=35) stage IV patients (p=0.0551). Distributions for stage I (n=0) and II (n=1) were not 
depicted. 
 
  
Table 1. Descriptive statistics of clinicopathological characteristics for OPSCC patients (ICART4 
cohort) in the analysis of centrosome amplification (clinical samples). 
Variable Level Number  Percentage 
Gender 
Male 68 79.4 
Female 30 30.6 
HPV Status 
 +ve 47 48 
 -ve 51 52 
Grade 
1 6 6.1 
2 49 50 
3 31 31.6 
N/A 12 12.2 
Stage I 0 0 
13 
II 1 1 
III 24 24.5 
IV 63 64.3 
N/A 10 10.2 
Tumor Site 
Tonsil 67 68.4 
Base of Tongue 13 13.3 
Soft Palate 13 13.3 
Tonsil+Base of Tongue 1 1 
N/A 4 4 
Alcohol 
No alcohol/Occasional  90 91.8 
Alcohol Abuse 8 8.2 
Smoking 
Never 32 32.7 
Previous 10 10.2 
Current  45 45.9 
N/A 11 11.2 
CA (%) 
Low (<23%) 38 38.8 
High (>23%) 60 61.2 
HPV +ve 
CA(%) 
Low (<23%) 21 44.7 
High (>23%) 26 55.3 
HPV -ve CA(%) 
Low (<23%) 17 33.3 
High (>23%) 34 66.7 
Chemotherapy 
Type 
None 50 51 
Concomitant 38 38.8 
Neoadjuvant 2 2 
Concomitant & 
Neoadjuvant 0 0 
Adjunctive 2 2 
N/A 6 6.1 
Radiotherapy 
Type 
None 7 7.1 
Primary 25 25.5 
Adjuvant 55 56.1 
Palliative 7 7.1 
N/A 4 4.1 
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Table 2. Multivariate analysis for high and low CA groups in HPV -ve OPSCCs 
 
3.2 Novel CA7 score based on CA-associated genes has prognostic value in HPV –ve 
HNSCCs 
 Given the association of CA with poor overall survival in HPV -ve OPSCCs, we 
wanted to evaluate whether centrosomal abnormalities in HPV -ve OPSCCs were 
accompanied by dysregulation of the genes associated with centrosome 
biogenesis/duplication. To this end, we used publicly available TCGA microarray data of 
HNSCC patients to evaluate gene expression levels for seven genes associated with 
CA43,47. By adding the log-transformed values, normalized gene expression for CCND1, 
NEK2, PIN1, TUBG1, PLK1, BIRC5 and AURKA were calculated into a cumulative score 
(CA7). First, we evaluated the CA7 score in all (n=521) HNSCCs regardless of subtypes 
and HPV status. Patients were stratified into high and low CA subgroups using the optimal 
CA7 score cut-point (based on the log-rank test). Our findings demonstrated that (Fig. 3A) 
high CA7 score HNSCCs (n=420) were associated with poorer survival (p=0.0389; HR 
1.497) when compared with the low CA7 HNSCCs, (n=101). Interestingly, among OPSCC 
patients (n=80; HPV -ve=26 and HPV +ve=54) we found that high CA7 score was 
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associated with poor overall survival (Fig. 3B) regardless of HPV status (p<0.0001; 
HR=11.369). 
 When we looked at the HPV -ve HNSCCs, we observed that CA7 score was not able 
to stratify this group into high- and low-risk subgroups significantly. Since HPV +ve and -ve 
tumors are distinct disease entities, we designed a subtype-specific weighted gene 
expression signature based on the appropriately weighted expression of the CA7 genes in 
each subgroup. To develop this signature, the expression for each CA7 gene was split into 
a high versus low expression subgroups through optimization of the log-rank test statistic, 
and then the Hazard Ratio parameter estimate for the high expression group was 
determined. High expression gene groups that had a negative impact on survival had a 
positive parameter estimate while genes that correlated positively with good prognosis had 
a negative parameter estimate. The total weighted sum, for each patient, was generated by 
adding the parameter estimates for each gene that had above threshold expression (if they 
were in the low expression group they were given a 0 for that gene weight). The cutoff 
between high and low weighted CA7 scores was also performed by finding the optimal log-
rank statistics. Interestingly, we observed that this new model was able to stratify HPV -ve 
HNSSCs with higher significance (HR=1.867; p<0.001). Among HPV -ve OPSCCs, high 
CA7 group (n=6) showed a strong trend towards poorer overall survival (HR=2.242; 
p=0.113) when compared to low CA7 group (n=20) (data not shown), but owing to the small 
sample size, we were not able to achieve statistical significance. 
 Given that the seven CA-associated genes were associated with poor prognosis in 
HPV -ve HNSCCs, we suspected that inhibitors of these genes should be effective on HPV 
-ve HNSCCs. To this end, utilizing publicly available CancerRxgene database we looked at 
the effect of Aurora A inhibitor in HPV -ve and HPV +ve HNSCC cell lines. As we expected, 
HPV -ve HNSCC cell lines were more susceptible to Aurora A inhibitor compared to HPV 
+ve, HNSCC cell lines (Fig. 4A). Thus, collectively these findings suggest that CA is 
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associated with high-risk HPV -ve OPSCCs can serve as a novel therapeutic target for HPV 
-ve subtype.  
Table 3. Descriptive statistics of clinicopathological characteristics for HNSCC patients in the 
cohort used for in silico analysis of the prognostic value of CA7 signature 
Variable Level Number  Percentage 
Gender 
Male 385 73.9 
Female 136 26.1 
HPV 
status 
HPV +ve 97 18.6 
HPV -ve 422 81 
N/A 2 0.4 
Grade 
1 62 11.9 
2 305 58.5 
3 125 24 
4 7 1.3 
X 18 3.5 
N/A 4 0.76 
Stage 
I 20 3.8 
II 98 18.8 
III 106 20.3 
IV 283 54.3 
N/A 14 2.9 
Tumor Site 
Alveolar 18 3.5 
Base of the tongue 28 5.4 
Buccal mucosa 22 4.22 
Floor of mouth 60 11.5 
Hypopharynx 10 1.9 
Larynx, nos 116 22.3 
Lip 3 0.6 
Oral cavity, nos 73 14 
Oral tongue 82 15.7 
Oropharynx 9 1.7 
Palate, hard 7 1.3 
Tongue, nos 47 9 
Tonsil 43 8.3 
N/A 3 0.6 
Smoking 
Never 117 22.5 
Previous 215 41.3 
Current  177 34 
N/A 12 2.3 
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Figure 3. Upregulation of CA7 genes is associated with poor overall survival in HNSCCs. (A) 
Kaplan Meier survival curves representing the survival probability of HNSCC patients stratified 
according to CA7 high (n=420) and CA7 low (n=101) expression levels (HR=1.497; p=0.0389). 
(B) Kaplan Meier survival curves representing the survival probability of OPSCC patients 
stratified according to CA7 high (n=28) and CA7 low (n=52) expression levels (HR=11.369; 
p<0.0001). (C) Kaplan Meier Survival curve of HPV -ve HNSCC patients stratified according to 
the weighted CA7 high (n=122) and CA7 low (n=300) expression levels (HR=1.867; p<0.001). 
(D) Forest plot of hazard ratios for each of the CA7 genes in HPV -ve HNSCCs. The blue lines 
represent 95% confidence intervals. The HR for each gene is considered to be significant 
(p<0.05) if the blue lines do not cross HR of 1.0.    
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Figure 4. HPV -ve HNSCC cell lines are more susceptible to inhibitos of CA-associated proteins 
compared to HPV +ve HNSCC cell lines. Bar graphs (derived from analysis of data from 
CancerRxgenome database) showing IC50 values of (A) ZM447439, Aurora A inhibitor and (B) 
Palbociclib, CDK4/6 inhibitor in HPV -ve and HPV +ve HNSCC cell lines. 
 
3.3 CA status correlates with HIF-1α expression and hypoxia gene score in HPV -ve 
OPSCC tumors  
 Tumor hypoxia has been consistently linked to worse response to radiotherapy and 
chemotherapy across many types of cancers leading to poor prognoses.48-50 Previous 
clinical studies determined HIF-1α as a poor prognostic factor in radiotherapy-treated HPV -
ve HNSCC51 and also suggested that  HIF-1α high, HPV -ve  OPSCC patients show worse 
prognosis when compared to those with HIF-1α high, HPV +ve OPSCCs.52 Based on our 
lab’s finding that hypoxia induces CA in breast tumors via HIF-1α, and given that HPV -ve 
tumors exhibit higher CA in clinical samples, we suspected that this subset of patients might 
have higher expression of HIF-1α. To test our hypothesis, we immunohistochemically 
stained the adjacent sections of the 87 OPSCC samples (used to quantify CA; Fig. 1) for 
HIF-1α. Nuclear HIF-1α weighted index (WI) was calculated as indicated in Materials and 
Methods. Patients were stratified into high- and low- HIF-1α expressing subgroups using 
the optimal HIF-1α expression cut-point (based on the log-rank test). We observed (Fig. 5B) 
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that high HIF-1α HPV -ve OPSCCs (n=30) showed higher CA (p=0.0479) when compared 
with low HIF-1α HPV -ve OPSCCs (n=12). The survival analysis (Fig. 5C) demonstrated 
that the high HIF-1α expressing group was associated with poorer overall survival 
(HR=3.191; p=0.0826) than the low HIF-1α subgroup. 
 Next, we evaluated if there was any difference in expression of hypoxia-associated 
genes in HPV -ve and HPV +ve HNSCCs. Herein, we used the same publicly available 
dataset (TCGA dataset) used in result section 1 to probe the 26-gene hypoxic signature.53,54 
Our results indicated significantly (p=3.77x10-7) higher expression of the total 26 hypoxia-
associated genes including HIF-1α in HPV -ve (n=422) head and neck tumors when 
compared to those of the HPV +ves (n=97) (Fig. 6A). When we further looked at the subset 
of only OPSCCs (based on the location of tumor- the base of tongue, tonsils, and 
oropharynx) among the whole cohort, we found similar results wherein, HPV -ve OPSCCs 
(n=26) showed significantly (p<0.001) higher expression of 26-gene hypoxia signature 
when compared with the HPV +ve OPSCCs (n=54) (Fig. 6B). Also, the hypoxia score was 
able to stratify the OPSCCs into high and low-risk groups. The high-hypoxia group was 
associated with significantly poorer overall survival when compared with lower hypoxia 
group (HR=3.297; p=0.0127). Interestingly, among the HPV -ve OPSCCs, high hypoxia 
HPV -ve OPSCCs exhibited poorer overall survival (HR=2.197; p=0.205) than the low 
hypoxia HPV -ve OPSCCs.  We also observed a positive correlation between the CA7 and 
Hypoxia 26 gene scores in HPV -ve OPSCCs (R=0.34760; p=0.0819). 
 Collectively, these findings confirm that there is a correlation between HIF-1α and CA 
in OPSCCs with higher significance in the HPV -ve tumors. These results strongly suggest 
that the CA observed in HPV -ve OPSCCs may be hypoxia-induced and may underlie their 
poor prognoses.  
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Figure 5. HPV -ve OPSCC tumors show a high association between CA and HIF-α expression. 
(A) Representative immunohistochemical micrographs of HPV +ve and HPV -ve OPSCC tumors 
stained for HIF-1α. (B) Box plot depicting the distribution of CA in HIF-1α-high (n=30) and low 
(n=12) HPV -ve tumors (p=0.0479). (C) Kaplan Meier survival analysis representing overall 
survival in HPV -ve OPSCCs stratified based on HIF-1α scores (HR=3.191; p=0.0826). 
 
 
Figure 6. Comparison of 26-gene hypoxia gene signatures of HNSCC tumors in TCGA. 
(A) Box whisker plot showing expression of the 26-gene hypoxia signature in HPV -ve (n=422) 
and HPV +ve (n=97) HNSCC patients (p=3.77x10-7). (B) Box whisker plot showing expression 
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of the 26-gene hypoxia signature in HPV -ve (n=26) and HPV +ve (n=54) OPSCC patients 
(p<0.001). 
3.4 HIF-1α downregulates miRNA-34a to induce CA via CCND1 overexpression  
Having established the relationship between hypoxia and CA in HPV -ve OPSCCs we next 
sought to delineate the possible role of HIF-1α in the induction of CA in OPSCC. Hypoxia 
mediates its function through a transcription factor hypoxia-inducible factor-1 alpha (HIF-1α), 
and changes in gene expression under hypoxia are due to the transcriptional regulation of 
hypoxia-regulated genes by HIF-1α. Studies have also shown that hypoxia and HIF-1α can 
regulate a panel of miRNAs55,56 and these miRNAs regulate the expression of genes involved in 
many vital events related to angiogenesis, tumorigenesis and even CA in multiple malignancies 
including head and neck cancer57. Therefore, we rationally hypothesized that hypoxia may 
induce expression of CA-associated genes through regulation of miRNAs in HPV -ve OPSCCs. 
To test this hypothesis, we used publicly available TCGA miRNA-seq data from 497 HNSCC 
patients. We analyzed expression of top 19 CA-associated miRNAs (list and expression 
reported in Table 3). Among these 19 miRNAs, 12 miRNAs were upregulated in HPV +ve and 7 
were upregulated in the HPV -ve OPSCCs. Interestingly, we observed significant 
overexpression of miR-34a in HPV +ve tumors compared to the HPV -ve tumors (p=0.000248). 
CCND1 mRNA is the known target of miR-34a which has been shown to downregulate cyclin 
D1 expression58. In line with this, we observed the expression levels of the CCND1 gene to be 
significantly downregulated in HPV +ve tumors (p=9.88 x 10-9) and there was a negative 
correlation between miR-34a and CCND1 (Fig. 7). Furthermore, HIF-1α, which is more highly 
expressed in HPV -ve tumors, represses the expression of miR-34a.59 Intriguingly, as 
mentioned above in the same dataset we observed significantly higher expression of HIF-1α in 
HPV -ve OPSCCs (Fig. 6). These findings further strengthen our model that CCND1 expression 
in HPV -ve OPSCC tumors is upregulated by HIF-1α-mediated downregulation of miR-34a, and 
upregulated CCND1 then drives CA in these tumors.  
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Table 4. List of CA associated miRNAs sorted by logFC values. FC values represent a ratio of 
HPV +ve and HPV -ve values. 
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Figure 7. HPV +ve HNSCC samples exhibit greater downregulation of CCND1 by miR-34a. 
Scatter plot representing the correlation between CCND1 gene expression and miR-34a 
expression in HPV +ve and HPV -ve HNSCCs. The red line indicates correlation for HPV -ve 
and blue line indicates correlation for HPV +ve. 
 
 To further bolster our in silico findings, we also examined the relationship of HIF-1α 
and cyclin D1 in clinical samples. To this end, we immunohistochemically stained the 
adjacent sections of the 87 OPSCCs samples used in result section 1 and 2. Nuclear cyclin 
D1 WI was calculated as indicated in Materials and Methods. We found that cyclin D1 
expression was significantly (p<0.0001) higher in the HPV -ve (n=43) OPSCCs when 
compared with the HPV +ve (n=44) OPSCCs (Fig. 8A, B) and high cyclin D1 expression 
was associated with poorer overall survival in OPSCCs (HR=3.409; p=0.0646) (Fig. 8C). 
Also, cyclin D1 was further able to stratify HPV -ve OPSCCs in high- and low-risk groups 
(HR=3.62; p=0.0152) (Fig. 8D). Furthermore, we observed a strong positive correlation 
between HIF-1α and cyclin D1 scores in HPV -ve OPSCCs (Spearman’s rho p=0.642; 
p<0.001). Past studies have confirmed the overexpression of cyclin D1 in promoting CA, 
aneuploidy, and tumorigenesis.60,61, In line with this we also observed that in HPV-ve 
OPSCCs the percent CA in tumor samples was positively correlated with the Cyclin D1 
expression (Spearman’s rho p  =  0.637; p  <0.001). Furthermore, utilizing publicly available 
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CancerRxgenome database we looked at the effect of CDK inhibitors (with correspondence 
to cyclin D1), in HPV -ve and HPV +ve HNSCC cell lines. As we expected, HPV -ve 
HNSCC cell lines were more susceptible to CDK inhibitor (Palbociclib) compared to HPV 
+ve, HNSCC cell lines (Fig. 4B). As a result, these findings substantiate the paradigm that 
hypoxia induces CA in HPV -ve OPSCCs, at least in part, by overexpression of cyclin 
D1.  
 
 
Figure 8. Cyclin D1 expression is upregulated in HPV -ve OPSCCs and is correlated with poor 
overall survival. 
(A) Immunohistochemical micrographs of HPV +ve and HPV -ve OPSCC tumors labeled with 
nuclear cyclin D1. (B) Box plot representing the distribution of cyclin D1 WI in HPV +ve (n=44) 
and HPV –ve (n=43) tumors (p<0.0001). (C) Kaplan Meier survival curves representing the 
overall survival of cyclin D1 high (n=28) and low (n=59) groups in HPV -ve and HPV +ve 
OPSCC patients (HR=3.409; p=0.0646). (D) Kaplan Meier survival curve representing the 
overall survival of cyclin D1 high (n=24) and low (n=19) groups in HPV -ve OPSCC patients 
(HR=3.626; p=0.0152).  
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 Finally, we wanted to see which marker (CA, HIF-1α, or cyclin D1) was best able to 
stratify HPV -ve OPSCCs into high and low-risk groups and would thus be most clinically 
informative. First, we performed a multivariate analysis, and noted that only CA showed a 
association with poor overall survival when other confounding factors like stage, therapy, 
gender and alcohol consumption and expression levels of HIF-1α and cyclin D1 were taken 
in account (HR=4.43; p=0.062) (Table 5A). Next, to measure the performance of prognostic 
models we used a measure of model fit, 2 Log Likelihood (-2LogL) (the model that 
minimized the -2LogL was considered superior). The results from this statistical test 
indicated that CA is the best-fit model (Table 5B). Similarly, when we performed the same 
test for our in silico findings, it also indicated the weighted CA7 score was stratifying the 
HPV -ve HNSCCs in high and low-risk groups better than the hypoxia score (Table 5C). 
Thus, collectively these findings, suggest that CA can serve as a clinically informative 
phenotypic biomarker for identification of high-risk HPV -ve OPSCC patients and can 
potentially also serve as a novel therapeutic target for these patients. 
 
Table 5. Multivariate analysis for HPV -ve OPSCCs comparing the high- and low-CA groups. 
(A) and (B) -2log L model fit test for clinical samples. (C) -2log L model fit test for in silico TCGA 
dataset.  
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4 DISCUSSION 
CA, a key driver of CIN and an early driver of intratumoral heterogeneity62, is a hallmark of 
cancer and is associated with tumorigenesis and tumor progression in multiple cancers 
including head and neck. Quantitation of CA in tumor samples can thus capture important risk-
predictive information and offer insights into the clinical course of multiple cancer types, 
including HNSCCs. Studies have shown that higher CA is associated with local recurrence in 
surgically-resected HNSSCs63. Another study in surgically-resected HNSCCs found that 
structural and numerical CA were able to better predict recurrence than other commonly used 
parameters like T stage; this study found a non-significant trend among the high-CA HNSSCs 
towards poor recurrence-free survival in these patients53,64. Furthermore, in another study, it has 
been reported that higher CA was associated with poor overall survival in HNSCCs 65. However, 
no studies to date have performed a rigorous comparison of CA in OPSCCs that differed in their 
HPV status, nor have they investigated the prognostic role of CA in HPV +ve/-ve OPSCCs after 
accounting for potential confounders like age, gender, stage, grade and HPV status. Previous 
studies also focused on upregulation of DDR and failure of cytokinesis as causes of CA in 
HNSCCs66 67. Another important mechanism that has been studied at length in generation of CA 
in HNSCCs is related to HPV infection, where due to the presence of E6 and E7 genes in HPV 
+ve HNSCCs18,19,20, it was presumed that this group exhibits higher CA when compared with 
HPV-ve HNSCCs. To shed light on these questions, we performed rigorous quantitation of CA 
(structural and numerical centrosomal aberrations) in a large cohort of HPV -ve and HPV +ve 
OPSCC tumor samples and explored the role of hypoxia - a hitherto overlooked driver of CA- in 
the generation of CA in HPV -ve tumors. 
Our findings from clinical samples uncovered that HPV -ve OPSCCs exhibited higher CA 
than HPV +ve OPSCCs, and that CA was associated with poorer overall survival in HPV -ve 
OPSCCs, even when all the other confounding factors were controlled for. In addition, higher 
CA was associated with poorer overall survival in OPSCCs, regardless of HPV status. These 
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findings were corroborated by our in silico analysis of CA-associated genes in the large, well-
annotated TCGA microarray dataset (Fig. 3). Genomic and proteomic research have revealed 
that HPV -ve HNSCCs exhibit high intratumoral heterogeneity that underlies therapeutic 
resistance and recurrence68. Our findings suggest that the higher CA observed in HPV -ve 
HNSCCs may drive higher CIN and intratumoral heterogeneity in HPV -ve OPSCC tumors, 
leading to therapy resistance and worse prognosis. Since CA can be induced by perturbations 
in the expression of many different genes, we rationally identified a set of 7 CA-associated 
genes commonly associated with centrosome structure/biogenesis whose dysregulation is 
known to induce CA. Impressively, this “CA7” gene signature was significantly prognostic in 
HNSCCs as well as in OPSCCs and was able to stratify HPV -ve HNSCCs into high and low-
risk groups.  
Our study further showed that the percentage of cells showing CA was strongly correlated 
with the nuclear WI for HIF-1α in HPV -ve OPSCCs and that a 26-gene hypoxia signature was 
able to significantly stratify HPV -ve OPSCCs in the TCGA dataset into high- and low-risk 
subgroups. These data strongly support that idea that hypoxia is likely to be a major driver of 
the CA. Our study also delineated the molecular mechanism whereby HIF-1α induces CA in 
HPV -ve OPSCCs - HIF-1α downregulates miR-34a that results in the strong upregulation of 
cyclin D1 and drives rampant CA in these tumors. The overexpression of cyclin D1 renders 
these tumors susceptible to the CDK4/6 inhibitor palbociclib as well as to Aurora A inhibitor 
ZM447439. Thus, our study has uncovered CA as an objectively evaluable and actionable 
phenotypic biomarker and has yielded novel insights into potential therapeutic targets for HPV -
ve OPSCC patients who are in dire need of new treatment approaches that could improve their 
outcomes. 
Among multiple factors, varied tumor microenvironment is one of the major contributing 
factors for the different biology in HPV -ve and HPV +ve OPSCCs69. Oxygen is necessary for 
radiosensitization, as ionizing radiation leads to a series of chemical reactions that contribute to 
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DNA damage.70 Hypoxic tumors are more resistant to treatments and are associated with poor 
prognosis across a variety of cancers. In line with this, we observed higher expression of HIF-1α 
in the HPV -ve OPSCCs, and high HIF-1α was strongly correlated with the percentage of cells 
showing high CA in HPV -ve OPSCCs.  However, contradicting reports can be found in the 
literature with regard to HIF-1α expression in HPV +ve versus HPV -ve tumors; one study 
reported that HIF-1α expression was higher in HPV +ve HNSCCs71, while a second study 
reported higher expression of HIF-1α in HPV -ve head and neck cell lines.72 Other endogenous 
hypoxia markers such as CA IX have also not shown definitive results73. These individual 
markers alone may not capture the entire picture of the hypoxic environment in HNSCCs. A 
more comprehensive approach of using a collection of hypoxia markers may be more pertinent 
in better accounting for intratumoral heterogeneity and cellular responses to hypoxia. Therefore, 
in this study, a previously established 26-gene signatures of hypoxia were used for in silico 
analyses on the publicly available dataset, revealing higher expression of hypoxia associated 
genes in HPV -ve OPSCCs and higher expression of these genes were associated with poor 
overall survival within this subset. With the understanding that hypoxia and the resulting HIF-1α 
activation can induce CA, it explains the higher CA observed in our HPV -ve OPSCC clinical 
samples and the corresponding poorer survival compared to HPV -ve OPSCCs.  
The analysis of miRNA expression in OPSCC has provided a possible mechanistic 
explanation for the link between hypoxia and CA. As key players of post-transcriptional 
regulation of gene expression, miRNAs are fundamental for normal biological processes by 
preventing the formation of the gene product. And just like oncogenes, miRNA deregulation can 
lead to a variety of cancers.74,75 Although miRNAs have been identified in OPSCC in relation to 
their prognostic value, there is a lack of characterization of their potential role in oncogenesis 
and in driving tumor evolution. In this study, we have newly identified miR-34a as a possible 
player in driving aggressive tumor characteristics in OPSCC through induction of CA. The 
deregulation of miR-34a has been revealed to be involved in different types of cancers. By 
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targeting CCND1, miR-34a controls the expression of cyclin D1, a protein whose upregulation 
triggers CA. Since hypoxia and HIF-1α have been shown to repress the expression of miR-
34a52,76 , miR-34a’s downregulation in HPV -ve tumors leads to cyclin D1 overexpression and 
CA. We observed similar findings in our clinical samples where HPV -ve OPSCCs expressed 
higher levels of cyclin D1, and its expression was associated with poor overall in these patients. 
Therefore, our findings indicate that HIF-1α-mediated downregulation of miR-34a in HPV -ve 
tumors drives its distinct tumor biology, and establish a causative link between two biological 
phenomena – hypoxia and CA – that co-occur in many solid tumors. 
Studies have shown that EGFR inhibitors such as Cetuximab are effective in treating 
HPV -ve HNSCCs. However, only a modest effect on survival has been shown when cetuximab 
was co-administered with conventional chemotherapy. Therefore, new molecular targets are 
required to improve survival in HPV -ve HNSCCs. Our study shows that the HPV -ve HNSCC 
cell lines are more sensitive to CDK 4/6, and Aurora A inhibitors when compared with HPV +ve 
HNSCC cells. This finding is in concordance with previous studies showing that HPV -ve 
HNSCCs are sensitive to treatment with CDK 4/6 inhibitor palbociclib and Aurora A inhibitors 
ZM447439. Thus, our results from in silico and clinical studies indicate that non-toxic 
centrosome declustering drugs (such as noscapinoids, griseofulvin, KifC1/HSET inhibitors, and 
PJ34), which selectively target cells with CA and compel them to construct a potentially lethal 
multipolar spindle during mitosis, might also be promising therapeutic agents for HPV -ve 
HNSCCs. 
Collectively, the data presented support the idea that hypoxia is likely to be a major 
driver of the CA observed in HPV -ve OPSCCs. Our study also delineated the molecular 
mechanism whereby HIF-1α induces CA in HPV -ve OPSCCs - HIF-1α downregulates miR-34a, 
which results in the strong upregulation of cyclinD1 and drives rampant CA in these tumors. 
Thus, our study has uncovered CA as an objectively evaluable and actionable phenotypic 
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biomarker and has yielded novel insights into potential therapeutic targets for HPV -ve OPSCCs 
that are in dire need of new and more effective treatment options. In conclusion, this is the first 
report to substantiate the previously unrecognized role of HIF-1α-induced CA in HPV -ve 
OPSSCs, revealing a molecular pathway that may be responsible for the CIN, intratumoral 
heterogeneity and poor prognosis associated with these tumors. The prognostic potential of CA 
is especially resounding within HPV -ve OPSSCs, facilitating enhanced identification of higher 
risk patients, influencing future treatment strategies, and providing a platform for the discovery 
of effective molecular targets.   
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